Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice

Figure 4

Chronic treatment with E2HSA improved glycemic control in spontaneous type 2 diabetes db/db mice. (a) Nonfasting blood glucose levels normalized by setting blood glucose levels in the control group to 100%. The mini figure shows the nonfasting blood glucose levels at 1 hour and 5 hours after E2HSA and exendin-4 administration on the first day. (b) Changes in fasting blood glucose levels relative to levels before E2HSA treatment. ((c) and (d)) Blood glucose curves and AUC of OGTT on the 2nd week. ((e) and (f)) Blood glucose curves and AUC of OGTT on the 5th week. (g) HbA1c levels on the 37th day. (h) Insulin/glucose ratios at 10 minutes following glucose challenge on the 5th week. Nor., db/m mice administered normal saline. Con., db/db mice administered normal saline. Data are expressed as mean ± S.E.M (-11). , , and versus Con.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)